Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases - Related Studies

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

This study is ongoing, but not recruiting participants.

Study NCT00080782. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Metastatic Cancer
		Prostate Cancer

2	Additional conditions recognized in this trial
		Neoplasm Metastasis
		Prostatic Neoplasms

3	More general conditions related to this trial
		Genital Diseases, Male
		Genital Neoplasms, Male
		Neoplasms
		Neoplasms by Site
		Neoplastic Processes
		Pathologic Processes
		Prostatic Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		celecoxib
		doxorubicin hydrochloride
		strontium chloride Sr 89

5	Additional drug interventions recognized in this trial
		Doxorubicin

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antibiotics, Antineoplastic
		Antineoplastic Agents
		Antirheumatic Agents
		Central Nervous System Agents
		Cyclooxygenase Inhibitors
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		National Cancer Institute (NCI)